Loading ...
Sorry, an error occurred while loading the content.

Fwd: The man who invented Glivec hails SC verdict

Expand Messages
  • Thiagarajan Arunachalam
    From: *karmayog - tanya* http://www.business-standard.com/article/companies/man-behind-glivec-hails-sc-verdict-113040200356_1.html Reghu Balakrishnan | Mumbai
    Message 1 of 1 , Apr 3, 2013
    • 0 Attachment
      From: karmayog - tanya

      http://www.business-standard.com/article/companies/man-behind-glivec-hails-sc-verdict-113040200356_1.html

      Reghu Balakrishnan | Mumbai April 3, 2013 Last Updated at 00:46 IST
      The man behind Glivec hails verdict
      Brian Druker, who invented the drug's molecule, says it would benefit
      patients in the short term

      Even though Novartis and other multinational corporations (MNCs) are upset
      with the Indian Supreme Court's decision to reject Novartis' patent claim on
      Glivec, the key man behind the popular cancer drug has welcomed the verdict,
      saying it would benefit patients.

      Brian Druker, director, Knight Cancer Institute at Oregon Health and
      Sciences University, is the man who invented the molecule - imatinib, the
      precursor to Gleevec (Glivec) - as a promising anti-cancer compound in
      1990s. "This patent decision clearly makes more affordable drugs available
      immediately and this is good for patients in the short term," Druker said in
      an email response to Business Standard.

      "I have consistently spoken out about what I view as the high price of
      drugs, but if we too severely restrict the price of medications, we may lose
      the ability to invest in new drugs," he added.

      In 2007, Druker reportedly said the price at which Novartis was selling
      imatinib around the world had caused him considerable discomfort.
      "Pharmaceutical companies that have invested in the development of medicines
      should achieve a return on their investments. But this does not mean the
      abuse of these exclusive rights by excessive prices and seeking patents over
      minor changes to extend monopoly prices. This goes against the spirit of the
      patent system and is not justified, given the vital investments made by the
      public sector over decades that make the discovery of these medicines
      possible," said Druker. His statement is widely used by pharma
      non-government organisations across India to challenge the claims of MNCs.

      Druker's effort to find a new drug for chronic myeloid leukemia (CML) was
      started in late 1980s, when he joined hands with industry scientists at
      Ciba-Geigy (now Novartis Pharmaceuticals). In 1993, he moved to Oregon
      Health Sciences University in Portland and continued his efforts. Imatinib
      was approved by the US Food and Drug Administration in May 2001 for use in
      CML.

      "The issue is, when does a country move from needing assistance to make
      drugs affordable, to being able to contribute more to drug discovery and
      innovation," said Druker.

      At present, India is at the receiving end after MNCs flayed the government's
      decision to allow compulsory licence for patented cancer drugs, which remain
      unaffordable to Indian patients. Recently, the Indian patent office issued a
      compulsory licence to Natco Pharma to manufacture the generic version of
      Nexavar, cancer drug owned by Bayer. Natco plans to sell the drug at Rs
      8,880 for a pack of 120 tablets / month, compared to Bayer's price of Rs 2.8
      lakh.

      "Whether patients will be adequately monitored is another issue and for the
      long-term. Whether this patent decision damages the drug discovery cycle
      remains to be seen," said Druker.


    Your message has been successfully submitted and would be delivered to recipients shortly.